Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in
the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid …

Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly
successful in decreasing disease severity; however, the recent emergence of the heavily …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing
antibodies and one of the most rapidly evolving domains, which can result in the emergence …

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has
been spreading rampantly. The global scientific community has responded rapidly to …